Co-targeting KRASG12D and the HER family is efficacious in colorectal cancer
Carcinogenesis · 2025
DOI: 10.1093/carcin/bgaf036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, 2025. Verfasst von Mary Kate Kilroy-Gehret und 6 weiteren Autor:innen. Beteiligte Einrichtung: James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, United States. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Receptor, ErbB-3. Die Arbeit nennt 52 Literaturangaben. Gefördert von: American Cancer Society, University of Cincinnati Cancer Center Pilot.
Abstract (Originalsprache)
Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide, with roughly 41% of CRC cases harboring a KRAS mutation. Acquired resistance to KRAS-targeted treatments has occurred with mechanisms including increased HER family expression among other receptor tyrosine kinases. HER3, a member of the HER family that is kinase impaired, has been shown to be a resistance mechanism upon inhibition of the HER family and downstream targets, including RAS/MEK/ERK and PI3K/AKT. We find that KRAS mutations tend to co-occur with HER3 alterations in a large panel of cancers and in CRCs. Our results show that both total and activated HER3 levels increase in CRC patient-derived organoids and cell lines after treatment with KRASG12D targeted agents, indicating that HER3 could be a potential adaptive response mechanism to KRAS-targeted therapy. Further, we found that genetic knock-down of KRAS and HER3 resulted in a reduction in the growth of CRC cells compared to a single knockdown of either KRAS or HER3. We observed that kinase-impaired HER3 binding partners, as assessed by immunoprecipitation, is cell dependent with EGFR binding HER3 in one cell line. After co-treating CRC cells with pan-HER inhibitors in combination with MRTX1133, a KRASG12D inhibitor, synergistic and additive effects in the reduction in cell growth were observed. Finally, we found that co-targeting KRASG12D mutant cells with a KRASG12D inhibitor and a HER3 antibody-drug conjugate further reduced cell viability. We posit that co-targeting both KRASG12D and HER3, whether directly or indirectly, is a potential therapeutic strategy in CRC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, United States.
- Cancer Research Scholars Program, College of Allied Health Sciences, University of Cincinnati, Cincinnati, OH 45267, United States.
ORCID-Profile: Mary Kate Kilroy-Gehret, SoYoung Park, Daniel Choi, Wasim Feroz, Rosalin Mishra, Joan T Garrett
Förderung
- American Cancer Society
- University of Cincinnati Cancer Center Pilot
Zitieren
APA
Kilroy-Gehret, M. K., Wischmeier, C., Park, S., Choi, D., Feroz, W., Mishra, R., & Garrett, J. T. (2025). Co-targeting KRASG12D and the HER family is efficacious in colorectal cancer. Carcinogenesis. https://doi.org/10.1093/carcin/bgaf036
Vancouver
Kilroy-Gehret MK, Wischmeier C, Park S, Choi D, Feroz W, Mishra R, et al. Co-targeting KRASG12D and the HER family is efficacious in colorectal cancer. Carcinogenesis. 2025. doi:10.1093/carcin/bgaf036
BibTeX
@article{KilroyGehret2025,
author = {Kilroy-Gehret, Mary Kate and Wischmeier, Cecilia and Park, SoYoung and Choi, Daniel and Feroz, Wasim and Mishra, Rosalin and Garrett, Joan T},
title = {Co-targeting KRASG12D and the HER family is efficacious in colorectal cancer},
journal = {Carcinogenesis},
year = {2025},
doi = {10.1093/carcin/bgaf036}
}
EUVIMED